INS and metabolic syndrome: As MetS represents a cluster of multiple risk factors, it requires polypharmacological treatment such as angiotensin-converting enzyme inhibitors or diuretics for lowering high blood pressure, fibrates for controlling abnormally increased TG levels, and peroxisome proliferator-activated receptor-γ agonists, insulin-sensitizing agents, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors or sodium-glucose cotransporter-2 inhibitors for reducing hyperglycemia [5].